Français
ItalianoBond AbbVie 4.875% ( US00287YDZ97 ) in USD
| Issuer | AbbVie | ||||||
| Market price |  102.71 % ⇌ |
||||||
| Country |  United States
|
||||||
| ISIN code |
 US00287YDZ97 ( in USD )
|
||||||
| Interest rate | 4.875% per year ( payment 2 times a year) | ||||||
| Maturity | 14/03/2030 | ||||||
|
Prospectus brochure in PDF format |
|||||||
| Minimal amount | / | ||||||
| Total amount | / | ||||||
| Cusip | 00287YDZ9 | ||||||
| Standard & Poor's ( S&P ) rating | A- ( Upper medium grade - Investment-grade ) | ||||||
| Moody's rating | A2 ( Upper medium grade - Investment-grade ) | ||||||
| Next Coupon | 15/09/2026 ( In 20 days ) | ||||||
| Detailed description |
AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology. The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YDZ97, pays a coupon of 4.875% per year. The coupons are paid 2 times per year and the Bond maturity is 14/03/2030 The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YDZ97, was rated A2 ( Upper medium grade - Investment-grade ) by Moody's credit rating agency. The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YDZ97, was rated A- ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency. |
||||||
| |||||||